Globus Medical (GMED)
(Delayed Data from NYSE)
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.88 USD
+1.34 (1.82%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $74.90 +0.02 (0.03%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
Zacks News
CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View
by Zacks Equity Research
Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.
Boston Scientific Stock Gains From Market Expansion, Innovation
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
by Zacks Equity Research
Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.
Gear Up for Globus Medical (GMED) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts
by Zacks Equity Research
Strength in AVNS' Digestive Health segment drives its third-quarter performance
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
by Zacks Equity Research
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
by Zacks Equity Research
GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock
by Zacks Equity Research
Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.
Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y
by Zacks Equity Research
NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
by Zacks Equity Research
TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.
ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock
by Zacks Equity Research
Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.
Is GMED Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Globus Medical's synergistic merger with NuVasive and a cadence of product launches bring optimism to investors.
TFX Stock to Gain From Launch of New Vascular Access Devices in Canada
by Zacks Equity Research
Teleflex launches the next-generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
by Zacks Equity Research
Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.
Intuitive Surgical Q3 Earnings Beat, Procedures Robust
by Zacks Equity Research
ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
Globus Medical Expands Orthopedic Trauma Portfolio With New Launches
by Zacks Equity Research
GMED launches ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws.
GMED or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMED vs. SONVY: Which Stock Is the Better Value Option?
Why Is Globus Medical (GMED) Down 0.2% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is It Apt to Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED's robust prospects in the musculoskeletal field and the synergies from the NuVasive merger bode well. Yet, macroeconomic issues can affect performance.
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
by Zacks Equity Research
Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
by Zacks Equity Research
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Globus Medical (GMED) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.